Latest News

  • Personalis ctDNA Test Paves Way for Medicare Reimbursement in Breast Cancer

    Diagnostics World | A retrospective study from Personalis for its NeXT Personal test, an ultra-sensitive circulating tumor DNA (ctDNA) test for cancer patients and survivors, has been published in Annals of Oncology. The study was conducted with researchers from The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust in the UK.

    Mar 6, 2025
  • Methylation Monitoring Predicts Pan-Cancer Outcomes

    Diagnostics World | In a paper published last month in Nature Scientific Reports, authors validate Northstar Response, BillionToOne's novel tissue-free circulating tumor DNA (ctDNA) liquid biopsy test that enables physicians to monitor cancer treatment response in Stage III-IV cancers with a blood draw.

    Mar 5, 2025
  • Pan-European Genomic Reanalysis Project Turns Up Over 500 Diagnoses

    Diagnostics World | A transcontinental collaborative effort brought together 300 experts from 12 European countries and Canada to try and crack the genetic cause of thousands of unsolved rare disease cases. Through data-sharing and genetic reanalysis, this “coalition of the willing” has most recently succeeded in providing more than 500 patients with a long-awaited diagnosis—and peace of mind to unaffected family members about whether they carry the risk variant.

    Mar 4, 2025
  • Dovetail’s Platform for Oncology Research, Novel iPSC Foundry, More

    Diagnostics World | Dovetail Genomics announced its early access services for FFPE (Formalin-Fixed Paraffin-Embedded) sample analysis; Cellino announced its collaboration with Mass General Brigham’s Gene and Cell Therapy Institute (GCTI) to launch the world’s first hospital-based autologous induced pluripotent stem cell (iPSC) Foundry; and more.

    Feb 27, 2025
  • Follow the Money: Radionuclide Therapies, GIP Antagonists for Obesity, More

    Diagnostics World | A transcontinental collaborative effort brought together 300 experts from 12 European countries and Canada to try and crack the genetic cause of thousands of unsolved rare disease cases. Through data-sharing and genetic reanalysis, this “coalition of the willing” has most recently succeeded in providing more than 500 patients with a long-awaited diagnosis—and peace of mind to unaffected family members about whether they carry the risk variant.

    Feb 26, 2025
  • University of Cambridge Develops ‘Sleep Pajamas’ For Monitoring Sleep Disorders

    Diagnostics World | Researchers at the University of Cambridge have developed washable and comfortable ‘smart pajamas’ to help monitor sleep disorders at home. The pajamas negate the need for sticky patches, monitoring equipment, or visiting sleep clinics for specialty tests.

    Feb 20, 2025
  • LinusBio Launches ClearStrand-ASD That Detects Autism With a Single Hair Strand

    Diagnostics World | Amid an industrywide shortage of workers and hospital capacity, a multimodal artificial intelligence (AI) platform providing real-time visibility into the clinical picture for patients is finding a national audience with health systems big and small who want to “make the right thing the easy thing to do” for their overburdened clinicians.

    Feb 13, 2025
  • Dual Biomarker Assay for Pancreatic Cancer to be Studied in CLIA Lab

    Diagnostics World | Two glycans are better than one when it comes to detecting pancreatic cancer that currently lacks a biomarker capable of accurately and reliably spotting the disease. The gold standard biomarker CA19-9, approved by the U.S. Food and Drug Administration (FDA) for monitoring response to treatment, correctly identifies only 44% of cases but the addition of CA199.STRA ramped that up to 71% while maintaining a low false positive rate in a recent case control study.

    Feb 11, 2025
  • Wearables Could Enable Continuous Monitoring of Inflammatory Diseases

    Diagnostics World | Physiological changes in the body driven by inflammation, as happens with inflammatory bowel disease (IBD) and rheumatoid arthritis, can be “easily and passively” measured with commercially available wearable devices, according to gastroenterologist Robert Hirten, M.D., associate professor of medicine and artificial intelligence and human health at the Icahn School of Medicine at Mount Sinai.

    Feb 5, 2025
  • High-Value Opportunities for Multimodal AI in Clinical Care and Research

    Diagnostics World | Amid an industrywide shortage of workers and hospital capacity, a multimodal artificial intelligence (AI) platform providing real-time visibility into the clinical picture for patients is finding a national audience with health systems big and small who want to “make the right thing the easy thing to do” for their overburdened clinicians.

    Feb 4, 2025
  • Follow the Money: OTC Diagnostics, Breath Biopsies, AI

    Diagnostics World | January’s funding focused on at-home cancer diagnostics, treatments for autoimmune disorders, and gene therapy for ophthalmology, Hepatitis B, and more.

    Jan 29, 2025
  • New Diagnostic Tools, MRD panels, New 23andMe Research Product

    Diagnostics World News | PathAI and Discovery Life Sciences launch partnership; new diagnostic tools for epilepsy, syphilis; OGT launches MRD panel; more.

    Jan 28, 2025
  • Quanterix Launches New Platform for Alzheimer’s Treatment Development, Big Plans for 2025

    Diagnostics World | At this year’s J.P. Morgan Healthcare Conference, Masoud Toloue, CEO of Quanterix, presented his company’s achievements of 2024, the acquisition of Akoya Biosciences, and their plans for the new year. Toloue opened with Quanterix’s mission, “The mission at Quanterix is to create the tools to enable discovery and better health.”

    Jan 23, 2025
  • Mount Sinai Develops Diagnostic AI Tool to Predict Cancer Patient Response to ICI Therapy

    Diagnostics World | Researchers at the Tisch Cancer Institute at Mount Sinai, in collaboration with Memorial Sloan Kettering Cancer Center (MSKCC), have unveiled SCORPIO, an artificial intelligence (AI) tool designed to predict cancer patients’ responses to immune checkpoint inhibitor (ICI) therapy. By focusing on diagnostic capabilities, SCORPIO uses routine blood tests and clinical data to identify patterns that correlate with treatment outcomes, offering an innovative approach to guiding immunotherapy decisions.

    Jan 22, 2025
  • At JPM: PacBio Turns Attention to LDTs

    Diagnostics World | PacBio’s president Christian Henry gave the sequencing company’s 43rd Annual J.P. Morgan Healthcare Conference address last week. And while Oxford Nanopore and Illumina both doubled down on proteomics and a multi-omic future, Henry stayed focus on PacBio’s mission to enable the promise of genomics to better human health.

    Jan 21, 2025
  • Grail at JPM: Looking Forward to Study Readouts, Prepped for Scale

    Diagnostics World | Grail presented for the first time at the 42rd Annual J.P. Morgan Healthcare conference today, and Bob Ragusa, CEO, took the stage. Grail was divested from Illumina and became an independent, publicly traded company in June 2024. But while the company structure has changed significantly in 2024, the mission has not, Ragusa said: detecting cancer early, when it can be cured.

    Jan 15, 2025
  • Mayo Clinic, NVIDIA Announce Collaboration on Digital Twins at J.P. Morgan Healthcare Conference

    Diagnostics World | Among the many partnerships and technical announcements made by NVIDIA during the company's Monday morning presentation at the 43rd Annual J.P. Morgan Healthcare Conference, NVIDIA focused several on innovation within the healthcare and life sciences industry.

    Jan 13, 2025
  • Beyond Breath: Researchers Look to Leverage VOCs from Skin, Urine, and More

    Diagnostics World | In the next phase of breath diagnostics, there is a promising area for future research: expanding upon the notion of “breath diagnostics” to leverage volatile organic compounds (VOCs) from elsewhere.  VOCs from urine could be used to detect prostate cancer, for example. If looked at carefully with the right AI tools, leveraging VOCs could lead to compelling healthcare solutions down the road.

    Jan 9, 2025
  • Chronic Fatigue Syndrome and Long COVID: Quest for Clues in Muscle Tissue

    Diagnostics World | An international team of researchers hope to identify molecular and cellular level changes in muscle tissue that can be used to help diagnose and treat chronic fatigue syndrome (CFS) and long COVID. The quest is being pursued from both the physiological and electrical perspectives to better understand the muscle damage seen with the debilitating and still-mysterious conditions that share some striking similarities.

    Jan 8, 2025
  • Trendspotting: Predictions for Diagnostics World in 2025

    Diagnostics World | 2024 was full of innovative ideas and achievements. We spoke with industry experts and leaders about what to expect in the new year. Here are the full predictions and trends, including more information on the impact of AI/ML, spatial biology, antimicrobial resistance, and more.

    Jan 7, 2025